<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37345645</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1758-2032</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Neurodegenerative disease management</Title><ISOAbbreviation>Neurodegener Dis Manag</ISOAbbreviation></Journal><ArticleTitle>A plain language summary of what clinical studies can tell us about the safety of evobrutinib - a potential treatment for multiple sclerosis.</ArticleTitle><Pagination><StartPage>207</StartPage><EndPage>213</EndPage><MedlinePgn>207-213</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2217/nmt-2023-0003</ELocationID><Abstract><AbstractText Label="WHAT IS THIS SUMMARY ABOUT?" NlmCategory="UNASSIGNED">This summary explains the findings from a recent investigation that combined the results of over 1000 people from three clinical studies to understand the safety of evobrutinib. Evobrutinib is an oral medication (taken by mouth), being researched as a potential treatment for multiple sclerosis (MS). This medication was also investigated in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Over 1000 people have taken evobrutinib as part of three separate phase 2 clinical studies. These studies looked at how much of the drug should be taken, how safe the drug is, and how well it might work for treating a certain medical condition.</AbstractText><AbstractText Label="WHAT WERE THE RESULTS?" NlmCategory="UNASSIGNED">Evobrutinib was well-tolerated by participants in all three studies. The number of side effects reported by participants taking the medication was very similar to those reported by participants taking the placebo (a 'dummy' treatment without a real drug). The most common side effects in clinical studies were urinary tract infections, headache, swelling of the nose and throat, diarrhoea and blood markers of potential liver damage (these returned to normal once the treatment was stopped).</AbstractText><AbstractText Label="WHAT DO THE RESULTS MEAN?" NlmCategory="UNASSIGNED">The safety data from all three clinical studies are encouraging and can be used to inform further research into using evobrutinib in MS. <b>Clinical Trial Registration:</b> NCT02975349 (multiple sclerosis), NCT03233230 (rheumatoid arthritis), NCT02975336 (systemic lupus erythematosus) (ClinicalTrials.gov).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Montalban</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology-Neuroimmunology, Centre d'Esclerosi M&#xfa;ltiple de Catalunya (Cemcat), Vall d'Hebron University Hospital, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallace</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cedars-Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Genovese</LastName><ForeName>Mark C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Division of Immunology &amp; Rheumatology, Stanford University, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomic</LastName><ForeName>Davorka</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Global Clinical Development, Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parsons-Rich</LastName><ForeName>Dana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Global Clinical Development, EMD Serono Research &amp; Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ECD-Early Clinical Development, Pfizer, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bolay</LastName><ForeName>Claire Le</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Biostatistics, Merck Healthcare KGaA, Darmstadt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kao</LastName><ForeName>Amy H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>EMD Serono Inc., Billerica, MA, USA, a healthcare business of Merck KGaA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guehring</LastName><ForeName>Hans</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Global Patient Safety, Merck Healthcare KGaA, Darmstadt, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03233230</AccessionNumber><AccessionNumber>NCT02975336</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neurodegener Dis Manag</MedlineTA><NlmUniqueID>101517977</NlmUniqueID><ISSNLinking>1758-2024</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>ZA45457L1K</RegistryNumber><NameOfSubstance UI="C000632111">evobrutinib</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="Y">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="Y">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">immunology</Keyword><Keyword MajorTopicYN="N">multiple sclerosis</Keyword><Keyword MajorTopicYN="N">rheumatology</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>22</Day><Hour>13</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37345645</ArticleId><ArticleId IdType="doi">10.2217/nmt-2023-0003</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>